Authors
Latest:
Metastatic Hormone-Sensitive Prostate Cancer Should Include Docetaxel Alongside ADTTreatment initiation for hormone-sensitive metastatic prostate cancer should include the addition of docetaxel to androgen deprivation therapy (ADT) as standard of care.
Latest:
Efficacy Results for Lorlatinib in Patients With ALK-Positive NSCLCAlice Shaw, MD, PhD, director of Thoracic Oncology at Massachusetts General Hospital, discussed the efficacy results from a recent trial investigating lorlatinib as treatment for patients with anaplastic lymphoma kinase-positive (ALK) non–small cell lung cancer that had failed other treatments prior, including crizotinib (Xalkori) and other multiple ALK tyrosine-kinase inhibitors.
Latest:
Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLCAlice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.
Latest:
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPCA review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Latest:
Study Finds Link Between E-Cigarette Use and Bladder CancerFindings from a recent pilot study done at the University of Pittsburgh Medical Center showed a potential link between e-cigarette use and bladder cancer.
Latest:
Concomitant Chemoradiotherapy Demonstrates Survival Benefit in Nasopharyngeal CarcinomaThe addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy (CRT) achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.
Latest:
The Importance of Multi-Gene Panel Testing for BRCA MutationsAllison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.
Latest:
Renal Complications Need Consideration in CIBDBisphosphonates and denosumab are bone-modifying agents that prevent or delay cancer-induced bone disease and skeletal-related events by inhibiting bone resorption.
Latest:
Overview of the STARTER-NET StudyExperts discuss an overview of the STARTER-NET study, emphasizing its goals, key outcomes, and potential impact on clinical practice.
Latest:
Neoadjuvant Chemotherapy for Patients With High-Grade Endometrial CancerAlon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.
Latest:
Dr. Amanda Kong on High Versus Low Volume Hospitals in the Treatment of Breast Cancer​Amanda L. Kong, MD, MS, FACS, discusses breast cancer care at high volume hospitals versus low volume hospitals. Kong says the study is the first one that looks at processes as a bundle and takes into account socioeconomic statuses of patients.
Latest:
Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid LeukemiaAlthough preclinical data are promising, there are many clinical challenges in developing CAR T-cell therapy in acute myeloid leukemia.
Latest:
Exploring Checkpoint Inhibition in Endometrial CancersAmanda Ramos, MD, a first-year fellow at the Massachusetts General Hospital in Boston, discusses the future potential of checkpoint inhibition therapy in the treatment of patients with recurrent endometrial cancers.
Latest:
Treatment Options for Relapsed/Refractory Solid Tumors in Pediatric and Young Adult PatientsAmi V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children’s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.
Latest:
The Evolving Role of Lenvatinib in the HCC Therapeutic LandscapePanelists discuss how lenvatinib has significantly impacted the systemic therapy landscape for hepatocellular carcinoma (HCC) across different stages. As a first-line treatment, it offers a viable alternative to sorafenib, demonstrating noninferior overall survival with improved progression-free survival and response rates. Its role extends to combination regimens and advanced-stage disease management.
Latest:
Dr. Amitabh Chak on New Screening Methods for Esophageal CancerAmitabh Chak, MD, MS, professor of Medicine, director, Clinical Research, Division of Gastroenterolgy Diseases, Case Western Reserve University, discusses advances in esophageal cancer. Chak says some of the more "exciting" developments in the treatment of the disease are transnasal endoscopy, as well as a new type of screening device that acts as a "pap smear" for the esophagus.
Latest:
Unanswered Questions Remain Regarding SBRT in Gastrointestinal CancersAmol K. Narang, MD, discusses the unanswered questions that still need to be addressed to further expand the role of stereotactic body radiation therapy in gastrointestinal cancers.
Latest:
Optimizing FLT3 Inhibitor Monotherapy in Acute Myeloid LeukemiaAcute myeloid leukemia (AML) therapy is guided mainly by cytogenetic profile, such as chromosomal duplication or deletion, and molecular mutations. <em>FLT3</em> mutations are the most common genetic abnormalities detected in patients with AML and are usually associated with a high relapse rate and short overall survival. Given the dismal outcomes in patients with <em>FLT3</em>-mutant AML, a great effort has been underway over the last several years to develop clinically effective FLT3 inhibitors.
Latest:
Dr. Amy Heimberger on Better Imaging and Combination Therapies in GlioblastomaHeimberger says the treatment paradigm's future is two-pronged, in that it will consist of both combination therapies that activate the immune system and prevent immunosuppression, as well as understand CT and MRI scans of brain cancer patients.
Latest:
Dr. Amy Heimberger on Immunotherapeutics in the Context of GlioblastomaAmy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM).
Latest:
Dr. Amy Johnson on Research Into Acalabrutinib as a Treatment for CLLAmy Johnson, PhD, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196).
Latest:
Select Ongoing Clinical Trials of PARP Inhibitors in Breast CancerMark E. Robson, MD, discusses the progress that has been seen in breast cancer care with the use of PARP inhibitors.
Latest:
Discontinuing Statins in Patients with Life-Limiting IllnessesAmy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses the results of a multisite randomized trial that examined continuing versus discontinuing statins in the setting of life-limiting illness.
Latest:
The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial CancerAna Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–high and microsatellite stable endometrial cancer.
Latest:
Dramatic Response to Olaparib in a Patient With Metastatic Castration- Resistant Prostate CancerMolecular tumor profiling is rapidly driving personalized medicine within oncology. The value of identifying a targetable mutation using next-generation sequencing for available therapies or clinical trials cannot be underestimated. Herein, we review essential considerations in the initial assessment, specialty referral, and sequencing of treatment for advanced prostate cancer with an identified actionable mutation.
Latest:
Results for the Combination of Nivolumab and Ibrutinib in Non-Hodgkin Lymphoma and CLLAnas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab and ibrutinib for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia.
